[3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-1H-indol-1-yl]acetic acid | 710957-06-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: [3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-1H-indol-1-yl]acetic acid
• 英文别名: 2-[3-(4-Chlorobenzoyl)-5-(4-chlorophenyl)indol-1-yl]acetic acid
• CAS: 710957-06-5
• 化学式: C₂₃H₁₅Cl₂NO₃
• 分子量: 424.283
• InChiKey: BHLXICYRKLZUGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  [3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-indol-1-yl]-acetic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 [3-(4-chlorobenzoyl)-5-(4-chlorophenyl)-1H-indol-1-yl]acetic acid
  参考文献：
  名称：

  Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

  摘要：

  提供了式I的3-羰基-1H-吲哚-1-基乙酸衍生物： 其中：R1，R2，R3，R4和R5如此处所定义，可用作纤溶障碍引起的疾病的纤溶酶原激活抑制剂-1（PAI-1）的抑制剂，例如深静脉血栓和冠心病以及肺纤维化的治疗。

  公开号：

  US20040122070A1

文献信息

• Inhibitors Of PAI-1 For Treatment Of Muscular Conditions
  申请人：Crandall LeRoy David

  公开号：US20070203220A1

  公开（公告）日：2007-08-30

  This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.

  这项发明描述了一种通过使用小分子PAI-1抑制剂治疗与各种情况相关的肌肉损伤、肌肉萎缩、肌肉退化、肌肉萎缩或肌肉修复率降低的新方法，例如肌营养不良。
• Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as ibhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Jennings D. Lee

  公开号：US20060178412A1

  公开（公告）日：2006-08-10

  Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives of formula I are provided: wherein: R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein which are useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.

  提供了公式I的3-羰基-1H-吲哚-1-基乙酸衍生物替代物：其中：R1，R2，R3，R4和R5如此定义，它们是用于抑制纤溶酶原激活抑制剂-1（PAI-1）以治疗由纤溶异常引起的疾病，如深静脉血栓和冠心病以及肺纤维化的有用药物。
• Proline bis-amide orexin receptor antagonists
  申请人：Bergman Jeffrey M.

  公开号：US20090118200A1

  公开（公告）日：2009-05-07

  The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及丙氨酸双酰胺化合物，其为促进素受体拮抗剂，可用于治疗或预防涉及促进素受体的神经和精神障碍和疾病。本发明还涉及包含这些化合物的制药组合物以及利用这些化合物和组合物预防或治疗涉及促进素受体的这些疾病的用途。
• SUBSTITUTED 3-CARBONYL-1-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
  申请人：Wyeth

  公开号：EP1569900B1

  公开（公告）日：2006-06-28
• US7078429B2
  申请人：——

  公开号：US7078429B2

  公开（公告）日：2006-07-18